Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Smartphone applications ("apps") with artificial intelligence (AI) algorithms are increasingly used in healthcare. Widespread adoption of these apps must be supported by a robust evidence-base and app manufacturers' claims appropriately regulated. Current CE marking assessment processes inadequately protect the public against the risks created by using smartphone diagnostic apps.

Original publication

DOI

10.1038/s41416-021-01302-3

Type

Journal article

Journal

Br J Cancer

Publication Date

05/2021

Volume

124

Pages

1749 - 1750

Keywords

Adult, Algorithms, Artificial Intelligence, Diagnostic Test Approval, Early Detection of Cancer, Europe, European Union, Evidence-Based Medicine, Humans, Mobile Applications, Precancerous Conditions, Risk Assessment, Sensitivity and Specificity, Skin Neoplasms, Smartphone, United States, United States Food and Drug Administration